Obstet Gynecol Sci.  2020 Jul;63(4):448-454. 10.5468/ogs.20004.

Evaluation of maternal rhesus blood type as a risk factor in adverse pregnancy outcomes in Korea: a nationwide health insurance database study

• Jin Y
• Dong M
• Yang SW
• Lee KM
• Han SW
• Seo SH
• Lee A
• Sohn IS
• Kwon HS
• Cho GJ
• Hwang HS

• KMID: 2505034
• DOI: http://doi.org/10.5468/ogs.20004

Abstract

Objectives
The current study aimed to investigate whether pregnancy outcomes are affected by maternal rhesus (Rh) status by comparing the primigravida pregnancy outcomes of Rh-negative women with those of Rh-positive women.
Methods
The study data were collected from the Korea National Health Insurance Claims Database and the National Health Screening Program for Infants and Children. In total, 1,664,882 primigravida women who gave birth between January 1, 2007 and December 31, 2014, were enrolled in this study. As the risk and severity of sensitization response increases with each subsequent pregnancy, only primigravida women were enrolled. The patients were divided into 2 groups according to Rh status, and the pregnancy outcomes were compared.
Results
In total, 1,661,320 women in the Rh-positive group and 3,290 in the Rh-negative group were assessed. With regard to adverse pregnancy outcomes, there was no statistically significant difference between the 2 groups in terms of the prevalence of preeclampsia, postpartum hemorrhage, abruptio placenta, placenta previa, and uterine artery embolization. A univariate analysis revealed that none of the adverse pregnancy outcomes were significantly correlated to Rh status (preeclampsia: odds ratio [OR], 1.00, 95% confidence interval [CI], 0.81–1.23; postpartum hemorrhage: OR, 1.10, 95% CI, 0.98–1.24; abruptio placenta: OR, 0.80, 95% CI, 0.46–1.37; and placenta previa: OR, 1.08, 95% CI, 0.78–1.42). The adjusted ORs of postpartum hemorrhage and preterm birth did not significantly differ.
Conclusion
Maternal Rh status is not associated with adverse outcomes in primigravida women.

Keyword

Rhesus blood-group system; Pregnancy outcomes; Gravidity; National health programs

Figure

• 

  Fig. 1. Flowchart of participant enrollment. NHSP-IC, National Health Screening Program for Infants and Children.

Reference

References

1. Landsteiner K, Levine P. On individual differences in human blood. J Exp Med. 1928; 47:757–75.

2. Wiener AS. History of the rhesus blood types. J Hist Med Allied Sci. 1952; 7:369–83.

3. Anstee DJ, Tanner MJ. Biochemical aspects of the blood group Rh (rhesus) antigens. Baillieres Clin Haematol. 1993; 6:401–22.

4. Liumbruno GM, Franchini M. Beyond immunohaematology: the role of the ABO blood group in human diseases. Blood Transfus. 2013; 11:491–9.

5. Franchini M, Mengoli C, Lippi G. Relationship between ABO blood group and pregnancy complications: a systematic literature analysis. Blood Transfus. 2016; 14:441–8.

6. Yu H, Xu N, Li ZK, Xia H, Ren HT, Li N, et al. Association of ABO blood groups and risk of gastric cancer. Scand J Surg. 2019; 1457496919863886.

7. Paquette M, Dufour R, Baass A. ABO blood group is a cardiovascular risk factor in patients with familial hypercholesterolemia. J Clin Lipidol. 2018; 12:383–389. e1.

8. Witsenburg CP, Rosendaal FR, Middeldorp JM, Van der Meer FJ, Scherjon SA. Factor VIII levels and the risk of pre-eclampsia, HELLP syndrome, pregnancy related hypertension and severe intrauterine growth retardation. Thromb Res. 2005; 115:387–92.

9. Seyfizadeh N, Seyfizadeh N, Yousefi B, Borzoueisileh S, Majidinia M, Shanehbandi D, et al. Is there association between ABO blood group and the risk factors of unfavorable outcomes of pregnancy? J Matern Fetal Neonatal Med. 2015; 28:578–82.

10. Duerbeck NB, Seeds JW. Rhesus immunization in pregnancy: a review. Obstet Gynecol Surv. 1993; 48:801–10.

11. Alpoim PN, de Barros Pinheiro M, Junqueira DR, Freitas LG, das Graças Carvalho M, Fernandes AP, et al. Preeclampsia and ABO blood groups: a systematic review and meta-analysis. Mol Biol Rep. 2013; 40:2253–61.

12. Phaloprakarn C, Tangjitgamol S. Maternal ABO blood group and adverse pregnancy outcomes. J Perinatol. 2013; 33:107–11.

13. Scott JR, Beer AA. Immunologic aspects of pre-eclampsia. Am J Obstet Gynecol. 1976; 125:418–27.

14. Finning K, Martin P, Summers J, Daniels G. Fetal genotyping for the K (Kell) and Rh C, c, and E blood groups on cell-free fetal DNA in maternal plasma. Transfusion. 2007; 47:2126–33.

15. Andersen AS, Praetorius L, Jørgensen HL, Lylloff K, Larsen KT. Prognostic value of screening for irregular antibodies late in pregnancy in rhesus positive women. Acta Obstet Gynecol Scand. 2002; 81:407–11.

16. Thompson PJ, Greenough A, Brooker R, Nicolaides KH, Gamsu HR. Antenatal diagnosis and outcome in hydrops fetalis. J Perinat Med. 1993; 21:63–7.

17. Kobets TV, Usachenko IE. Risk factors of complicated postnatal period in low birth weight infants. Tsitol Genet. 2001; 35:49–53.

18. Fan J, Lee BK, Wikman AT, Johansson S, Reilly M. Associations of rhesus and non-rhesus maternal red blood cell alloimmunization with stillbirth and preterm birth. Int J Epidemiol. 2014; 43:1123–31.

19. Zipursky A, Bhutani VK, Odame I. Rhesus disease: a global prevention strategy. Lancet Child Adolesc Health. 2018; 2:536–42.

20. Bel Hadj I, Boukhris R, Khalsi F, Namouchi M, Bougmiza I, Tinsa F, et al. ABO hemolytic disease of newborn : does newborn’s blood group a risk factor? Tunis Med. 2019; 97:455–60.

21. Fyfe TM, Ritchey MJ, Taruc C, Crompton D, Galliford B, Perrin R. Appropriate provision of anti-D prophylaxis to RhD negative pregnant women: a scoping review. BMC Pregnancy Childbirth. 2014; 14:411.

22. Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006; 367:1066–74.

23. May D. Letter: Maternal blood group A and pre-eclampsia. BMJ. 1973; 4:738.

24. Lee BK, Zhang Z, Wikman A, Lindqvist PG, Reilly M. ABO and RhD blood groups and gestational hypertensive disorders: a population-based cohort study. BJOG. 2012; 119:1232–7.

25. Chen Y, Chen C, Ke X, Xiong L, Shi Y, Li J, et al. Analysis of circulating cholesterol levels as a mediator of an association between ABO blood group and coronary heart disease. Circ Cardiovasc Genet. 2014; 7:43–8.

26. Chou ST, Westhoff CM. Molecular biology of the Rh system: clinical considerations for transfusion in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2009; 178–84.

27. Smits-Wintjens VE, Walther FJ, Lopriore E. Rhesus haemolytic disease of the newborn: postnatal management, associated morbidity and long-term outcome. Semin Fetal Neonatal Med. 2008; 13:265–71.